Adagio Medical Holdings Inc（ADGM）の財務ADGMAdagio Medical Holdings Inc

Evaluating the bottom line, Adagio Medical Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -657.76%, provide a clear picture of how effectively ADGM converts its operational activities into shareholder value.

In the context of the broader market, ADGM competes directly with industry leaders such as NXL and VBIO. With a market capitalization of $2.82M, it holds a leading position in the sector. When comparing efficiency, ADGM's gross margin of N/A stands against NXL's 73.16% and VBIO's N/A. Such benchmarking helps identify whether Adagio Medical Holdings Inc is trading at a premium or discount relative to its financial performance.

Adagio Medical has shown a gradual improvement in financial performance, with a reduced net loss of $7.0 million in Q1 2026 compared to $7.7 million in Q1 2025. The EPS has improved from -0.21 to -0.30, indicating some progress in cost management.